Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03840278 · ClinicalTrials.gov registry record · Phase 2
The Bihormonal iLet Bionic Pancreas Feasibility Study
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03840278: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT03840278 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03840278, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Our objective is to evaluate the function of the bihormonal configuration of the ILet bionic pancreas delivering dasiglucagon when compared to the insulin-only configuration of the ILet bionic pancreas in a home-use study in adults with type 1 diabetes.
Interventions
- DRUG Dasiglucagon
- DEVICE Bihormonal iLet Bionic Pancreas
- DEVICE Insulin-only Bionic Pancreas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03840278
The ClinicalTrials.gov registry entry for NCT03840278 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dasiglucagon is the first listed.
NCT03840278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03840278 about?
NCT03840278 is a clinical study titled "The Bihormonal iLet Bionic Pancreas Feasibility Study". Our objective is to evaluate the function of the bihormonal configuration of the ILet bionic pancreas delivering dasiglucagon when compared to the insulin-only configuration of the ILet bionic pancreas in a home-use study in adults with type 1 diabetes.
What is the current status of trial NCT03840278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2019-05-15. Estimated completion is 2019-07-03.
What interventions are being tested in trial NCT03840278?
The interventions under investigation include: Dasiglucagon (DRUG), Bihormonal iLet Bionic Pancreas (DEVICE), Insulin-only Bionic Pancreas (DEVICE).
Who is sponsoring clinical trial NCT03840278?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.